{"organizations": [], "uuid": "a1ca900a20ab380731a35c2b242a29670cac78de", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2016/10/10/104006682-GettyImages-AQ2442-001.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19746125/device/rss/rss.xml", "section_title": "Top News and Analysis (pro)", "url": "https://www.cnbc.com/2018/05/18/johnson-johnson-scraps-alzheimers-trials-on-safety-concerns.html", "country": "US", "domain_rank": 767, "title": "Johnson & Johnson scraps Alzheimer's drug trials on safety concerns", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-05-18T21:41:00.000+03:00", "replies_count": 0, "uuid": "a1ca900a20ab380731a35c2b242a29670cac78de"}, "author": "", "url": "https://www.cnbc.com/2018/05/18/johnson-johnson-scraps-alzheimers-trials-on-safety-concerns.html", "ord_in_thread": 0, "title": "Johnson & Johnson scraps Alzheimer's drug trials on safety concerns", "locations": [], "entities": {"persons": [{"name": "johnson", "sentiment": "negative"}, {"name": "john livzey", "sentiment": "none"}, {"name": "janssen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "johnson & johnson", "sentiment": "negative"}, {"name": "modern medicine johnson & johnson", "sentiment": "negative"}, {"name": "mins ago reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.\nSome trial participants showed serious elevations of liver enzymes and the company concluded that the benefit-risk ratio offered by the drug, atabecestat, no longer supported its development, said Janssen , a unit of Johnson and Johnson.\nAtabecestat belongs to a class of experimental Alzheimer's drugs called BACE inhibitors that block an enzyme involved in the production of a protein that creates brain plaques, which are considered a major cause for the disease.\nAnalysts expect the successful development of a treatment for the disease, which affects about 5.7 million Americans, to virtually guarantee multi-billion dollar annual sales.\nHowever, several drugmakers, including Pfizer , Merck and Co , have been forced to abandon trials over lack of effectiveness or safety concerns.\nEli Lilly and AstraZeneca are testing their BACE inhibitor, lanabecestat, in late-stage trials and are due to report results next year.\nJohnson & Johnson was testing atabecestat to slow cognitive decline in certain patients identified to be progressing to Alzheimer's dementia.", "external_links": ["http://www.janssen.com/update-janssens-bace-inhibitor-program"], "published": "2018-05-18T21:41:00.000+03:00", "crawled": "2018-05-18T21:47:59.002+03:00", "highlightTitle": ""}